Literature DB >> 1854033

Fluoride metabolites after prolonged exposure of volunteers and patients to desflurane.

T S Sutton1, D D Koblin, L D Gruenke, R B Weiskopf, I J Rampil, L Waskell, E I Eger.   

Abstract

We examined the metabolism of desflurane in 13 healthy volunteers given 7.35 +/- 0.81 MAC-hours (mean +/- SD) of desflurane and 26 surgical patients given 3.08 +/- 1.84 MAC-hours (mean +/- SD). Markers of desflurane metabolism included fluoride ion measured via an ion-specific electrode, nonvolatile organic fluoride measured after sodium fusion of urine samples, and trifluoroacetic acid determined by a gas chromatographic-mass spectrometric method. In both volunteer and patient groups, postanesthesia serum fluoride ion concentrations did not differ from background fluoride ion concentrations. Similarly, postanesthesia urinary excretion of fluoride ion and organic fluoride in volunteers was comparable to preanesthesia excretion rates. However, small but significant levels of trifluoroacetic acid were found in both serum and urine from volunteers after exposure to desflurane. A peak serum concentration of 0.38 +/- 0.17 mumol/L of trifluoroacetic acid and a peak urinary excretion rate of 0.169 +/- 0.107 mumol/h were detected in volunteers at 24 h after desflurane exposure. Although these increases in trifluoroacetic acid after exposure to desflurane were statistically significant, they are approximately 10-fold less than levels seen after exposure to isoflurane. Thus, desflurane strongly resists biodegradation, but a small amount is metabolized in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854033     DOI: 10.1213/00000539-199108000-00011

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  16 in total

1.  The effects of isoflurane and desflurane on cognitive function in humans.

Authors:  Bin Zhang; Ming Tian; Yu Zhen; Yun Yue; Janet Sherman; Hui Zheng; Shuren Li; Rudolph E Tanzi; Edward R Marcantonio; Zhongcong Xie
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

2.  Desflurane: the dawn of a new era?

Authors:  J Lerman
Journal:  Can J Anaesth       Date:  1991-11       Impact factor: 5.063

Review 3.  [Perioperative anesthesia management of extended partial liver resection. Pathophysiology of hepatic diseases and functional signs of hepatic failure].

Authors:  S Herz; G Puhl; C Spies; D Jörres; P Neuhaus; C von Heymann
Journal:  Anaesthesist       Date:  2011-02       Impact factor: 1.041

Review 4.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 5.  Clinical and economic factors important to anaesthetic choice for day-case surgery.

Authors:  E I Eger; P F White; M S Bogetz
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

6.  Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes.

Authors:  H Yin; M W Anders; K R Korzekwa; L Higgins; K E Thummel; E D Kharasch; J P Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Influence of desflurane, isoflurane and halothane on regional tissue perfusion in dogs.

Authors:  J C Hartman; P S Pagel; L T Proctor; J P Kampine; W T Schmeling; D C Warltier
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 8.  Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  [Desflurane in acute intermittent porphyria].

Authors:  M Messmer; F Gerheuser; H Forst
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 10.  Desflurane clinical pharmacokinetics and pharmacodynamics.

Authors:  J E Caldwell
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.